Review





Similar Products

e2 ag0292 proteins  (Proteintech)
85
Proteintech e2 ag0292 proteins
E2 Ag0292 Proteins, supplied by Proteintech, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/e2 ag0292 proteins/product/Proteintech
Average 85 stars, based on 1 article reviews
e2 ag0292 proteins - by Bioz Stars, 2026-05
85/100 stars
  Buy from Supplier
recombinant human ube2n protein ag0292  (Proteintech)
85
Proteintech recombinant human ube2n protein ag0292
Recombinant Human Ube2n Protein Ag0292, supplied by Proteintech, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human ube2n protein ag0292/product/Proteintech
Average 85 stars, based on 1 article reviews
recombinant human ube2n protein ag0292 - by Bioz Stars, 2026-05
85/100 stars
  Buy from Supplier
ubc13 ube2n  (Proteintech)
93
Proteintech ubc13 ube2n
Ubc13 Ube2n, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ubc13 ube2n/product/Proteintech
Average 93 stars, based on 1 article reviews
ubc13 ube2n - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
ube2n  (Akizuki Denshi Tsusho Co Ltd)
86
Akizuki Denshi Tsusho Co Ltd ube2n
Ube2n, supplied by Akizuki Denshi Tsusho Co Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ube2n/product/Akizuki Denshi Tsusho Co Ltd
Average 86 stars, based on 1 article reviews
ube2n - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
ube2n  (Proteintech)
93
Proteintech ube2n
Ube2n, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ube2n/product/Proteintech
Average 93 stars, based on 1 article reviews
ube2n - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
ube2n  (Proteostasis Therapeutics)
86
Proteostasis Therapeutics ube2n
Context-dependent dual roles of the immunoproteasome in cancer. The immunoproteasome (IP) exerts divergent functions depending on tumor type and microenvironmental context. On the pro-tumor side (red), IP activity sustains chronic inflammation, promotes IL-17/LMP7-driven prostate cancer progression, maintains AML stemness (PSMB10, <t>UBE2N),</t> rewires epigenetic and metabolic programs (DNMT1/3B loss, MCL-1 survival), and supports immune evasion via the USP24–STAT3–PD1 axis. Conversely, in immunogenic contexts (green), IP enhances tumor suppression by broadening the immunopeptidome and unmasking neoantigens, promoting CD8 + T-cell responses, with PSMB9 acting as a tumor suppressor in melanoma, glutamate flux inhibition boosting antigenicity in CRC, and dual MCL-1/MEK inhibition restoring therapy sensitivity in TNBC/IBC. High IP expression aligns with favorable prognosis in melanoma, bladder cancer, and TNBC. Notably, IP is dispensable for leukemia infected-cell vaccine efficacy (exception). Collectively, these findings position the IP as a context-dependent regulator, balancing between tumor-promoting inflammation and antigen-driven immune surveillance.
Ube2n, supplied by Proteostasis Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ube2n/product/Proteostasis Therapeutics
Average 86 stars, based on 1 article reviews
ube2n - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
anti ubc13  (Cell Signaling Technology Inc)
94
Cell Signaling Technology Inc anti ubc13
Context-dependent dual roles of the immunoproteasome in cancer. The immunoproteasome (IP) exerts divergent functions depending on tumor type and microenvironmental context. On the pro-tumor side (red), IP activity sustains chronic inflammation, promotes IL-17/LMP7-driven prostate cancer progression, maintains AML stemness (PSMB10, <t>UBE2N),</t> rewires epigenetic and metabolic programs (DNMT1/3B loss, MCL-1 survival), and supports immune evasion via the USP24–STAT3–PD1 axis. Conversely, in immunogenic contexts (green), IP enhances tumor suppression by broadening the immunopeptidome and unmasking neoantigens, promoting CD8 + T-cell responses, with PSMB9 acting as a tumor suppressor in melanoma, glutamate flux inhibition boosting antigenicity in CRC, and dual MCL-1/MEK inhibition restoring therapy sensitivity in TNBC/IBC. High IP expression aligns with favorable prognosis in melanoma, bladder cancer, and TNBC. Notably, IP is dispensable for leukemia infected-cell vaccine efficacy (exception). Collectively, these findings position the IP as a context-dependent regulator, balancing between tumor-promoting inflammation and antigen-driven immune surveillance.
Anti Ubc13, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti ubc13/product/Cell Signaling Technology Inc
Average 94 stars, based on 1 article reviews
anti ubc13 - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
4919s  (Cell Signaling Technology Inc)
93
Cell Signaling Technology Inc 4919s
Context-dependent dual roles of the immunoproteasome in cancer. The immunoproteasome (IP) exerts divergent functions depending on tumor type and microenvironmental context. On the pro-tumor side (red), IP activity sustains chronic inflammation, promotes IL-17/LMP7-driven prostate cancer progression, maintains AML stemness (PSMB10, <t>UBE2N),</t> rewires epigenetic and metabolic programs (DNMT1/3B loss, MCL-1 survival), and supports immune evasion via the USP24–STAT3–PD1 axis. Conversely, in immunogenic contexts (green), IP enhances tumor suppression by broadening the immunopeptidome and unmasking neoantigens, promoting CD8 + T-cell responses, with PSMB9 acting as a tumor suppressor in melanoma, glutamate flux inhibition boosting antigenicity in CRC, and dual MCL-1/MEK inhibition restoring therapy sensitivity in TNBC/IBC. High IP expression aligns with favorable prognosis in melanoma, bladder cancer, and TNBC. Notably, IP is dispensable for leukemia infected-cell vaccine efficacy (exception). Collectively, these findings position the IP as a context-dependent regulator, balancing between tumor-promoting inflammation and antigen-driven immune surveillance.
4919s, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/4919s/product/Cell Signaling Technology Inc
Average 93 stars, based on 1 article reviews
4919s - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
anti ube2n antibody  (Proteintech)
93
Proteintech anti ube2n antibody
Context-dependent dual roles of the immunoproteasome in cancer. The immunoproteasome (IP) exerts divergent functions depending on tumor type and microenvironmental context. On the pro-tumor side (red), IP activity sustains chronic inflammation, promotes IL-17/LMP7-driven prostate cancer progression, maintains AML stemness (PSMB10, <t>UBE2N),</t> rewires epigenetic and metabolic programs (DNMT1/3B loss, MCL-1 survival), and supports immune evasion via the USP24–STAT3–PD1 axis. Conversely, in immunogenic contexts (green), IP enhances tumor suppression by broadening the immunopeptidome and unmasking neoantigens, promoting CD8 + T-cell responses, with PSMB9 acting as a tumor suppressor in melanoma, glutamate flux inhibition boosting antigenicity in CRC, and dual MCL-1/MEK inhibition restoring therapy sensitivity in TNBC/IBC. High IP expression aligns with favorable prognosis in melanoma, bladder cancer, and TNBC. Notably, IP is dispensable for leukemia infected-cell vaccine efficacy (exception). Collectively, these findings position the IP as a context-dependent regulator, balancing between tumor-promoting inflammation and antigen-driven immune surveillance.
Anti Ube2n Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti ube2n antibody/product/Proteintech
Average 93 stars, based on 1 article reviews
anti ube2n antibody - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
ubiquitin-conjugating enzyme ube2n  (Proteostasis Therapeutics)
90
Proteostasis Therapeutics ubiquitin-conjugating enzyme ube2n
Context-dependent dual roles of the immunoproteasome in cancer. The immunoproteasome (IP) exerts divergent functions depending on tumor type and microenvironmental context. On the pro-tumor side (red), IP activity sustains chronic inflammation, promotes IL-17/LMP7-driven prostate cancer progression, maintains AML stemness (PSMB10, <t>UBE2N),</t> rewires epigenetic and metabolic programs (DNMT1/3B loss, MCL-1 survival), and supports immune evasion via the USP24–STAT3–PD1 axis. Conversely, in immunogenic contexts (green), IP enhances tumor suppression by broadening the immunopeptidome and unmasking neoantigens, promoting CD8 + T-cell responses, with PSMB9 acting as a tumor suppressor in melanoma, glutamate flux inhibition boosting antigenicity in CRC, and dual MCL-1/MEK inhibition restoring therapy sensitivity in TNBC/IBC. High IP expression aligns with favorable prognosis in melanoma, bladder cancer, and TNBC. Notably, IP is dispensable for leukemia infected-cell vaccine efficacy (exception). Collectively, these findings position the IP as a context-dependent regulator, balancing between tumor-promoting inflammation and antigen-driven immune surveillance.
Ubiquitin Conjugating Enzyme Ube2n, supplied by Proteostasis Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ubiquitin-conjugating enzyme ube2n/product/Proteostasis Therapeutics
Average 90 stars, based on 1 article reviews
ubiquitin-conjugating enzyme ube2n - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


Context-dependent dual roles of the immunoproteasome in cancer. The immunoproteasome (IP) exerts divergent functions depending on tumor type and microenvironmental context. On the pro-tumor side (red), IP activity sustains chronic inflammation, promotes IL-17/LMP7-driven prostate cancer progression, maintains AML stemness (PSMB10, UBE2N), rewires epigenetic and metabolic programs (DNMT1/3B loss, MCL-1 survival), and supports immune evasion via the USP24–STAT3–PD1 axis. Conversely, in immunogenic contexts (green), IP enhances tumor suppression by broadening the immunopeptidome and unmasking neoantigens, promoting CD8 + T-cell responses, with PSMB9 acting as a tumor suppressor in melanoma, glutamate flux inhibition boosting antigenicity in CRC, and dual MCL-1/MEK inhibition restoring therapy sensitivity in TNBC/IBC. High IP expression aligns with favorable prognosis in melanoma, bladder cancer, and TNBC. Notably, IP is dispensable for leukemia infected-cell vaccine efficacy (exception). Collectively, these findings position the IP as a context-dependent regulator, balancing between tumor-promoting inflammation and antigen-driven immune surveillance.

Journal: Frontiers in Oncology

Article Title: Rewiring tumor visibility: The immunopeptidome as a dynamic interface between antigen processing, microenvironmental stress, and immune recognition

doi: 10.3389/fonc.2025.1691719

Figure Lengend Snippet: Context-dependent dual roles of the immunoproteasome in cancer. The immunoproteasome (IP) exerts divergent functions depending on tumor type and microenvironmental context. On the pro-tumor side (red), IP activity sustains chronic inflammation, promotes IL-17/LMP7-driven prostate cancer progression, maintains AML stemness (PSMB10, UBE2N), rewires epigenetic and metabolic programs (DNMT1/3B loss, MCL-1 survival), and supports immune evasion via the USP24–STAT3–PD1 axis. Conversely, in immunogenic contexts (green), IP enhances tumor suppression by broadening the immunopeptidome and unmasking neoantigens, promoting CD8 + T-cell responses, with PSMB9 acting as a tumor suppressor in melanoma, glutamate flux inhibition boosting antigenicity in CRC, and dual MCL-1/MEK inhibition restoring therapy sensitivity in TNBC/IBC. High IP expression aligns with favorable prognosis in melanoma, bladder cancer, and TNBC. Notably, IP is dispensable for leukemia infected-cell vaccine efficacy (exception). Collectively, these findings position the IP as a context-dependent regulator, balancing between tumor-promoting inflammation and antigen-driven immune surveillance.

Article Snippet: AML – UBE2N and proteostasis , UBE2N stabilizes proteins via K63 ubiquitination; its inhibition triggers K48-linked degradation through immunoproteasome, suppressing AML. , UBE2N is a vulnerability in immunoproteasome-positive AML; inhibition may serve as therapeutic strategy. , ( ) .

Techniques: Activity Assay, Immunopeptidomics, Inhibition, Expressing, Infection